<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200527047578N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-09-28</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>Effect of zinc in reduce of post operative sore througth</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of zinc impregnated pack (compared to traditional methods) on reducing the incidence of sore throat in patients undergoing Septorhinoplasty</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-08-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>220</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/49347</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: The sampling method of this study is based on gradual referrals of patients and rhinoplasty surgery is based on random blocks whose sequences are randomly assigned through Random allocation software. The relevant list is kept in the ENT Research Center and after starting the study, based on a random list assigned to four groups (1)  pharyngeal pack of wet Vibrille with normal saline (2)  pharyngeal   pack of  gas Wet with normal saline (3)  zinc-impregnated Vibrilie  pack (4)  normal saline-damped vibrille, Blinding description: After obtaining the agreement of the ethics committee of Guilan University of Medical Sciences, a written agreement will be given to all patients participating in this study, in which the risks, benefits and steps of the work will be explained. The study will be designed randomly. So that patients will be unaware of their group.
220 patients who are candidates for septorhinoplasty surgery who are class I or II (ASA) and are candidates for general anesthesia and GA and receiving endotracheal intubation will be randomly assigned to a single blind blind study.</study_design>
      <phase>3</phase>
      <hc_freetext>1- The effect of zinc impregnated pharyngeal pack in comparison with other conventional methods on sore throat after septorhinoplasty 2_ The effect of zinc impregnated pharyngeal pack on postoperative vomiting.</hc_freetext>
      <i_freetext>Intervention 1: All patients participating in this study will be given a written agreement outlining the risks, benefits, and steps involved. Patients are randomly divided into four  intervention groups ( without control group ): (1) Patients with a pharyngeal pack made of wet vibrile with normal saline. BPI wibril made in Iran - Iran Medical Bands Manufacturing Company - will be used for the pharyngeal pack. The vibrils are the same size as the cut gas. To prepare the pack, the vibrils will be rolled in containers containing 0.9% normal saline to be evenly impregnated with the above solution. Intervention 2: Intervention group: In the second group, the bottom pack of the throat made of gas impregnated with zinc solution will be placed. 10 C 10 cm Cm made of English yarn 1/20- Number of yarn strands per square centimeter  According to standard 3061- Density of yarn per 10 cm  According to standard 3061- Density of powder at 10 cm  According to standard 3061- Width of gas yarn at least 5 mm /0. Zinc sulfate heptahydrate solution of Behsan Sar company is white and soluble in water, it will be used to impregnate the gas.To prepare the gas pack, it will be rolled in containers containing zinc sulfate heptahydrate solution to be uniformly impregnated with the above solutions. Intervention 3: Intervention group: In the third group, wet Vibrile intervention with N / S will be used. Intervention group. The properties of Vibrile and Normal Saline are in accordance with the explanations given in the previous interventions. Intervention 4: Intervention group:: In the fourth intervention group, Vibrile impregnated with zinc solution will be placed. The specifications of Vibrile and Zinc used and how to use it are in accordance with the previous cases.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
deidentified individual participant data (IPD) collected in this study
study protocol
 statistical analysis plan
clinical study reports

When:
beginning from 2021-2022

To whom:
academic researchers

Conditions:
only academic researchers

Where to obtain:
corresponding author/Dr Haddadi
so_haddadi@yahoo.com

How to obtain:
They send their request with academic e-mail./among one month

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fateme Taghi Pour Salehi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Valiasr Boulevard, at the end of Fathi Alley, No. 3</address>
        <city>Roudsar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4481873111</zip>
        <telephone>+98 13 4263 3310</telephone>
        <email>sroudsari@yahoo.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fateme Taghi Pour Salehi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Valiasr Boulevard, at the end of Fathi Alley, No. 3</address>
        <city>Roudsar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4481873111</zip>
        <telephone>+98 13 4263 3310</telephone>
        <email>sroudsari@yahoo.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>candidates for septorhinoplasty
class 1 or 2 ASA
receiving GA and septorhinoplasty</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>55 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>patient with History of  sore throat
upper respiratory tract disease
active common cold
positive history of receiving analgesic before surgery
drug addiction
positive history of difficult intubation
allergic reaction to zinc</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>All patients participating in this study will be given a written agreement outlining the risks, benefits, and steps involved. Patients are randomly divided into four  intervention groups ( without control group ): (1) Patients with a pharyngeal pack made of wet vibrile with normal saline. BPI wibril made in Iran - Iran Medical Bands Manufacturing Company - will be used for the pharyngeal pack. The vibrils are the same size as the cut gas. To prepare the pack, the vibrils will be rolled in containers containing 0.9% normal saline to be evenly impregnated with the above solution.</i_keyword>
      <i_keyword>Intervention group: In the second group, the bottom pack of the throat made of gas impregnated with zinc solution will be placed. 10 C 10 cm Cm made of English yarn 1/20- Number of yarn strands per square centimeter  According to standard 3061- Density of yarn per 10 cm  According to standard 3061- Density of powder at 10 cm  According to standard 3061- Width of gas yarn at least 5 mm /0. Zinc sulfate heptahydrate solution of Behsan Sar company is white and soluble in water, it will be used to impregnate the gas.To prepare the gas pack, it will be rolled in containers containing zinc sulfate heptahydrate solution to be uniformly impregnated with the above solutions.</i_keyword>
      <i_keyword>Intervention group: In the third group, wet Vibrile intervention with N / S will be used. Intervention group. The properties of Vibrile and Normal Saline are in accordance with the explanations given in the previous interventions</i_keyword>
      <i_keyword>Intervention group:: In the fourth intervention group, Vibrile impregnated with zinc solution will be placed. The specifications of Vibrile and Zinc used and how to use it are in accordance with the previous cases</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Postoperative sore throat with standard rating system and postoperative vomiting nausea (Verbal rating scale. Timepoint: Postoperative sore throat and postoperative vomiting nausea will be assessed at 0,2,4,6,24 hours. Method of measurement: Sore throat will be assessed with a standard rating system. (Zero hour) Post intensity is divided into four categories 0-3.0: Absence of sore throat, 1: Existence of mild discomfort that is expressed only by asking questions.2: The presence of moderate sore throat, which manifests itself.3: Existence of very severe sore throat that causes voice change and voice violence.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Guilan Medical University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-12-21</approval_date>
        <contact_name>Ethics Committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>Valiasr Boulevard, at the end of Fathi Alley, No. 3 roudsar Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
